Immunoisolation of tumor cells: Generation of antitumor immunity through indirect presentation of antigen

Journal of Immunotherapy

Volumn 20, Issue 2, 1997, Pages 131-137

  Geller, Robin L ^a   Neuenfeldt, Steven ^a   Levon, Steven A ^a   Maryanov, David A ^a   Thomas, Tracy J ^a   Brauker, James H ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Antigen presentation; Immunoisolation; Tumor immunotherapy; Tumor vaccines

Indexed keywords

TUMOR VACCINE;

ADENOCARCINOMA; ANIMAL CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL STIMULATION; DEVICE; GENE THERAPY; IMMUNE RESPONSE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL;

EID: 0031463909     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199703000-00005     Document Type: Article

References (36)

1. Bast RC, Mills GB, Gibson S, Boyer CM. Tumor immunology. In: Holland JF, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaum RR. Cancer medicine, 4th ed. Baltimore: Williams and Wilkins, 1997, 207-42.
2. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5: 153-64.
3. Pardoll DM. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 1993;5:719-25.
4. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon-γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
5. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
6. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
7. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
8. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppressed tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
9. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
10. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogated tumorigenicity and induces anti-tumoral immunity in mice. Hum Gene Ther 1993;4:703-11.
11. Porgador A, Tzehoval E, Vadal E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6 or interferon-γ genes. J Immunother 1993;14:191-201.
12. Ohira T, Ohe Y, Heike Y, et al. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Ther 1994;1:269-75.
13. Townsend SE. Allison JP. Tumor rejection after direct stimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
14. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993;259:94-7.
15. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1993;71:1093-102.
16. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman G, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90.
17. Plautz GE, Yang Z-Y, Wu B-Y, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-9.
18. Algire GH, Legallais FY. Recent developments in the transparent-chamber technique as adapted to the mouse. J Natl Cancer Inst 1949;10:225-53.
19. Lepeintre J, Briandet H, Moussy F, et al. Ex vivo evaluation in normal dogs of insulin released by a bioartificial pancreas containing isolated rat islets of Langerhans. Artif Organs 1990;14:20-7.
20. Altman JJ, Manoux A, Callard P, et al. Successful pancreatic xenografts using semipermeable membrane [Abstract]. Artif Organs 1981;5:776-9.
21. Siebers U, Zekorn T, Bretzel RG, et al. Histocompatibility of semipermeable membranes for implantable diffusion devices (bioartificial pancreas). Transplant Proc 1990;22:834-5.
22. Altman JJ, Houlbert D, Galletti PM. Progress in artificial organs - 1985. Cleveland: ISAO Press, 1986:627.
23. Theodorou NA, Howell SL. An assessment of diffusion chambers for use in pancreatic islet cell transplantation. Transplantation 1979;27:350-3.
24. Stillstrom J. Induction of SV-40-tumor immunity by SV-40-transformed cells in diffusion chambers. Acta Pathol Microbiol Scand 1974;82:676-86.
25. Conley FK. Transplantation of nervous system tumors in diffusion chambers. J Neurosurg 1974;41:332-8.
26. Rumi L, Pasqualini CD, Rabasa SL. Growth of sarcoma 180 in splenectomized mice bearing diffusion chambers containing spleen or tumor cells. Eur J Cancer 1995;7:551-5.
27. Brauker JH, Carr-Brendel V, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane architecture. J Biomed Mat Res 1995;29:1517-24.
28. Brauker J, Martinson LA, Young SK, Johnson RC. Local inflammatory response around diffusion chambers containing xenografts. Transplantation 1996;61:1671-7.
29. Loeffler CM, Smyth MJ, Longo DL, et al. Immunoregulation in cancer bearing hosts: downregulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol 1992; 149:949-56.
30. Neuenfeldt S, Brauker J, Clarke R. Ported tissue implant systems and methods of using same. United States Patent number 5,545,233, 1996.
31. Klein S, Jasnis MA, Diament M, Davel L, Aguirre J, deBonaparte YP. Immunomodulation by soluble factors from tumor cells cultured in vivo in diffusion chambers. Tumor Biol 1994;15:160-5.
32. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994; 152:2324-32.
33. Matzinger P. Tolerance, danger and the extended family. Ann Rev Immunol 1994;12:901-1045.
34. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss Jr H. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994;179:865-72.
35. Adler FL, Fishman M. Adjuvant effect of diffusion chambers on soluble antigens. Proc Soc Exp Biol Med 1962;111:691-5.
36. Katsanis E, Bausero MA, Panoskaltsis-Mortari A, et al. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduced their capacity to induce systemic immunity. Cancer Gene Ther 1996;3:75-82.